GW Pharmaceuticals (Jazz Pharmaceuticals)
About GW Pharmaceuticals (Jazz Pharmaceuticals)
GW Pharmaceuticals, now part of Jazz Pharmaceuticals, is the world's leading cannabinoid pharmaceutical company and creator of Epidiolex, the first FDA-approved plant-derived cannabinoid medicine. Based in Cambridge, UK, GW pioneered the development of prescription cannabinoid medicines through rigorous clinical trials. The company's Epidiolex is approved for treating severe forms of epilepsy including Dravet and Lennox-Gastaut syndromes.
Key Facts
- 1Created Epidiolex, the first FDA-approved plant-derived cannabinoid medicine
- 2Acquired by Jazz Pharmaceuticals for USD 7.2 billion in 2021
- 3Epidiolex generates over USD 700 million in annual revenue
- 4Sativex is approved in over 25 countries for multiple sclerosis spasticity
Latest News
UBS Upgrades Jazz Pharma to Buy With $307 Target on Cannabis Portfolio
UBS raises JAZZ to Buy rating with $307 price target, citing strong fundamentals in Epidiolex cannabis franchise and pipeline potential driving investor optimism.
Jazz Pharmaceuticals Catches Analyst Upgrade Amid Cannabis Portfolio Shift
JAZZ stock gains momentum as Wall Street analysts recognize value in diversified pharmaceutical portfolio including Epidiolex cannabis-derived treatments.
Jazz Pharma Draws Analyst Attention Amid Cannabis Portfolio Shift
Wall Street analysts reassess Jazz Pharmaceuticals as the company navigates its cannabis-derived drug portfolio and broader pharmaceutical operations.
Jazz Pharma Q1 Beat Drives Cannabis Analysts to Raise Price Targets
JAZZ shares climb as Epidiolex revenue growth and expanded guidance prompt Wall Street upgrades across multiple firms.
Jazz Pharma Q1 Earnings: Cannabis Portfolio Drives Revenue Beat
Jazz Pharmaceuticals reports strong Q1 results with cannabis-derived medications outperforming expectations, boosting investor confidence in pharma cannabis plays.
Frequently Asked Questions
What is Epidiolex used for?
Epidiolex is a purified cannabidiol (CBD) oral solution approved by the FDA and EMA for treating seizures associated with Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex in patients one year of age and older.
Is GW Pharmaceuticals still an independent company?
No, GW Pharmaceuticals was acquired by Jazz Pharmaceuticals in 2021 for approximately USD 7.2 billion. Its cannabinoid medicines, including Epidiolex and Sativex, are now part of Jazz's neuroscience portfolio.
More Cannabis Companies in Cambridge
Cannabis Laws
Products
- Epidiolex (cannabidiol oral solution)
- Sativex (nabiximols oromucosal spray)
- Pipeline cannabinoid medicines
Specialties
Company Details
- Type
- Medical & Pharma
- Location
- Cambridge, United Kingdom
- Founded
- 1998
- Publicly Traded
- Yes
- Ticker
- NASDAQ:JAZZ